Ophthalmic drug discovery and development using artificial intelligence and digital health technologies

Area of Science:

• Ophthalmology
• Pharmacology
• Biotechnology

Background:

• Drug discovery and development are lengthy, costly, and complex global endeavors.
• Artificial intelligence (AI) and digital health technologies offer transformative potential across all stages of pharmaceutical development.
• Ophthalmology serves as a key area for demonstrating AI's impact on drug discovery.

Purpose of the Study:

• To review recent advancements in AI and digital health within ophthalmology drug discovery and development.
• To highlight how AI can optimize various phases of the drug development pipeline.
• To underscore the need for regulatory frameworks for AI in ocular drug development.

Main Methods:

• Leveraging machine learning algorithms and extensive clinical and multiomics datasets.
• Analyzing AI applications in pre-clinical target identification, lead compound optimization, and predictive modeling (pharmacokinetics, pharmacodynamics, toxicity).
• Examining the role of AI-assisted multi-modal ocular biomarkers for treatment monitoring and personalized medicine.

Main Results:

• AI enables rapid identification and validation of drug targets.
• Machine learning optimizes lead compounds and predicts drug properties, enhancing efficiency.
• AI-driven ocular biomarkers improve treatment monitoring and facilitate personalized medicine approaches.
• Integration of AI significantly shortens development timelines, reduces costs, and boosts success rates.

Conclusions:

• AI and digital health innovations are revolutionizing ophthalmology drug discovery and development.
• AI integration enhances efficiency, reduces costs, and increases the success rate of new drug development.
• Standardized regulations for AI in ocular drug development are crucial for safe and equitable implementation.